CYT-303

N/A

Report date: 2026/04/22 20:01:10

Base Information

Drug NameCYT-303
Drug Alias NameCYT-303NY-303
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionNatural killer cells stimulantsAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsNatural cytotoxicity triggering receptor 1 agonists
TargetsNatural cytotoxicity triggering receptor 1Glypican-3
Therapy Area/IndicationsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCytovia Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesCytoLynx Therapeutics IncNAYA Biosciences IncCytovia Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsCarcinoma, Hepatocellular
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A